News | June 16, 2014

New Data Presented on Neuraceq Amyloid Plaque Imaging Agent at SNMMI 2014

June 16, 2014 — Piramal Imaging released details from research presented at the 2014 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in St. Louis. Research findings relating to the development and approval of Neuraceq (florbetaben F18 injection) were presented during the AD II: Advanced Approaches Session.

“The strength of our partnership with the research community has been on display throughout SNMMI,” said Andrew Stephens, M.D., chief medical officer, Piramal Imaging. “It is this partnership that allows us to push the innovation envelope for Piramal and molecular imaging as a field. The research presented here will be the basis for product advancements for years to come.”

At SNMMI there was a specific focus on science that improved the understanding of the value of beta-amyloid imaging as a tool for assessing patients with cognitive impairment. As independent researchers, these clinical experts discussed uses of beta-amyloid agents that are not completely reflected in the label approved by the U.S. Food and Drug Administration (FDA). Nevertheless, they highlight the emerging science underlying this new diagnostic tool. The three presentations highlighted below, each led by different key researchers, offered new insight into the clinical value and application for Neuraceq:

  • In a presentation titled “A negative florbetaben PET scan reliably excludes AD pathology as confirmed by histopathology,” John Seibyl, M.D., CEO of Molecular NeuroImaging and clinical professor of neurology at Yale University, focused on the very high negative predictive value of Neuraceq scans.
  • In his presentation “Efficacy and reliability of the visual assessment of 18F-florbetaben PET scans in the detection of beta-amyloid neuritic plaques in the brain,” Osama Sabri, M.D., Ph.D., University of Leipzig, Germany, revealed that the robustness of the visual scan assessment method developed for Neuraceq results in high sensitivity and specificity, even in challenging scans and restrictive reading conditions.
  • Henryk Barthel, M.D., Ph.D., University of Leipzig, Germany, presented “Early ß-amyloid PET images are a valuable surrogate biomarker of neuronal injury in dementia patients,” which showed that a single tracer injection may provide information on both neuronal integrity (as FDG) and beta-amyloid deposition.

Neuraceq was approved in the United States and European Union earlier this year. It is indicated for positron emission tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive decline.

For more information:

Related Content

Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
News | Ultrasound Imaging | March 21, 2018
Key processes in the body are controlled by the concentration of calcium in and around cells. A team from the Technical...
FDA Clears CereMetrix’s Neuroimaging Analytics and Clinical Workflow Platform
Technology | Neuro Imaging | March 15, 2018
March 15, 2018 – CereMetrix, a subsidiary of CereHealth Corp., ha
The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain.

This figure shows two different brains that are aligned to a common template space for comparison. The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain. CREDIT: Zachariah Reagh

News | Nuclear Imaging | March 08, 2018
As we get older, it's not uncommon to experience "senior moments," in which we forget where we parked our car or call...
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
Radiography Education Enrollment Shows Marginal Rise in 2017
News | Radiology Business | February 15, 2018
Directors of radiography educational programs report the number of enrolled students increased slightly in 2017, while...
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
MedyMatch Receives FDA Device Designation for Intracranial Hemorrhage Software
News | Computed Tomography (CT) | February 01, 2018
February 1, 2018 – MedyMatch Technology, a company focused on helping physicians provide accurate patient assessment
Overlay Init